Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
Amanda Foskett, Christina Manley, Rebecca Naramore, Ira K Gordon, Bridget M Stewart, Chand Khanna The Oncology Service, LLC, Leesburg, VA, USA Abstract: Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The U...
Guardado en:
Autores principales: | Foskett A, Manley C, Naramore R, Gordon IK, Stewart BM, Khanna C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a466842168cd4b3f8669b4a77ca74883 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sorafenib induced acral pigmentation: A new entity
por: Mrinal Gupta, et al.
Publicado: (2015) -
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Liming Zheng, et al.
Publicado: (2021) -
Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
por: Jingyao Wei, et al.
Publicado: (2021) -
Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
por: Javier Aubán-Pariente, et al.
Publicado: (2021) -
Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej K, et al.
Publicado: (2021)